C B G

M E B

College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board

Graadt van Roggenweg 500
3531 AH Utrecht
The Netherlands

DECENTRALIZED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Thyroxanil S tablets for dogs and cats

NL/V/195/001

AND

Thyroxanil L tablets for dogs and cats

NL/V/195/002

Created: December 2019

MODULE 1

PRODUCT SUMMARY

EU Procedure number	NL/V/0195/001-002/DC
Name, strength and pharmaceutical form	Thyroxanil S, 200 microgram tablets for dogs and cats Thyroxanil L, 600 microgram tablets for dogs and cats
Applicant	Le Vet Beheer B.V. Wilgenweg 7 3421TV Oudewater The Netherlands
Active substance(s)	Levothyroxine sodium
ATC Vetcode	QH03AA01
Target species	Dogs and cats
Indication for use	Treatment of primary and secondary hypothyroidism.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicines Agencies website (http://www.HMA.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended (for both products).
Date of completion of the original decentralised procedure	24 February 2016
Date product first authorised in the Reference Member State (MRP only)	N/A
Concerned Member States for original procedure	AT, BE, BG, CY, CZ, DE, DK, EE, EL, ES, FI, FR, HR, HU, IE, IS, IT, LT, LU, LV, NO, PL, PT, RO, SE, SI, SK, UK

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.
The product is safe for the user and for the environment, when used as recommended.
Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC. The overall risk/benefit analysis is in favour of granting a marketing authorisation.

Thyroxanil S and Thyroxanil L are generic products. The reference products are Thyroxal 200 µg tablets for dogs and cats (REG NL 104831) and Thyroxal 600 µg tablets for dogs and cats (REG NL 110962), which are registered in the Netherlands since 2009 and 2013, respectively. The reference veterinary medicinal product for data protection is L-Thyroxine tablets, 200 µg (REG NL 9049), registered since 2002 by Aesculaap B.V., The Netherlands. The initial application for L-Thyroxine tablets, 200 µg (REG NL 9049) was assessed before there was a requirement to have a public assessment report; therefore no details in this section are available.

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The product contains levothyroxine sodium (0.200 mg = 200 µg per tablet or 0.600 mg = 600 µg per tablet), magnesium oxide (heavy), cellulose microcrystalline, sodium starch glycolate (type A), and magnesium stearate.

The container/closure system consists of PVC/Aluminium blisters.

The choice of the formulation is justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is levothyroxine sodium, an established substance described in the European Veterinary Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Scientific data and/or certificates of suitability issued by the EDQM have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

D. Control on intermediate products

The tests performed during production are described and the results of 3 consecutive runs, conforming to the specifications, are provided.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

Shelf life of the veterinary medicinal product as packaged for sale: 2 years

G. Other Information

None.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmaco-toxicological tests are not required. The pharmaco-toxicological aspects of this product are identical to the reference product.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline which are mentioned in the SPC as follows: “This product contains a high concentration of L-thyroxine sodium and may be harmful when ingested, particularly for children. Pregnant women should handle this veterinary medicinal product with caution. Wash hands after handling the tablets. In the case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Any unused tablet portion(s) should be returned to the open blister, stored out of the sight and reach of children and always be used at the next administration.”

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines. The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the product is used only to treat individual non-food animals.

IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Veterinary Medicines Agencies website (www.HMA.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Summary of change (Application number)	**Section updated in Module 3**	**Approval date**
Change of the product name in Poland (NL/V/0195/002/IB/001)	N/A	21 December 2016
Introduction of a new Pharmacovigilance system (NL/V/xxxx/WS/021)	N/A	12 July 2019